Truist Financial Corp, an institutional investor, recently acquired a new position in Amedisys, Inc. (NASDAQ: AMED), a leading healthcare services provider in the United States. According to its filing with the Securities and Exchange Commission, Truist Financial Corp acquired 2,784 shares of Amedisys’ stock during the first quarter, with an estimated value of $205,000.
Amedisys recently released its quarterly earnings data on July 26th. The company reported earnings per share (EPS) of $1.37 for the quarter, surpassing analysts’ consensus estimates of $1.09 by $0.28. The company generated revenue of $552.97 million during the quarter, slightly below the consensus estimate of $568.18 million. Amedisys experienced a decrease in quarterly revenue compared to the same period last year; however, it still managed to maintain a net margin of 0.10% and a return on equity of 14.00%. In the previous year’s corresponding quarter, the company earned $1.47 per share.
For the current fiscal year, research analysts project that Amedisys will achieve earnings per share of 4.42. Despite experiencing a slight decline in revenue during this particular quarter compared to last year’s figure, Amedisys has shown consistent growth over time and is projected to perform well throughout the remainder of the fiscal year.
Amedisys operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. Its Home Health segment provides various services to individuals recovering from surgery, dealing with chronic disabilities or terminal illnesses within their homes. The segment employs skilled nurses who aid in patients’ recovery while also preventing avoidable hospital readmissions through their expertise and care coordination efforts. In addition to nursing services, Amedisys offers rehabilitation therapy services specializing in physical, speech, and occupational therapy. The company also provides social workers and aides to assist patients under their care.
As Amedisys continues to provide essential healthcare services, its strategic approach within the home health sector is noteworthy. By focusing on patient recovery, reducing hospital readmissions, and providing comprehensive care, Amedisys has positioned itself as a reliable and effective player in the healthcare industry.
With Truist Financial Corp’s recent acquisition of Amedisys’ stock, it highlights not only the confidence this institutional investor has in the company but also the potential for growth and profitability that lies ahead. As we progress through the fiscal year, it will be interesting to monitor Amedisys’ performance and assess how it navigates challenges within the healthcare landscape while striving to improve patient outcomes.
Hedge Funds and Institutional Investors Make Significant Changes to Amedisys, Inc. Holdings
Amedisys, Inc. (AMED) recently caught the attention of numerous hedge funds and institutional investors who have made significant modifications to their holdings of the company’s stock. BlackRock Inc., for instance, saw a 3.7% increase in its holdings during the first quarter, now owning 3,896,785 shares valued at $671,378,000. Vanguard Group Inc., on the other hand, experienced a 0.3% growth in its holdings in the third quarter, adding an additional 10,457 shares worth $294,438,000 to its portfolio.
Wellington Management Group LLP raised its holdings by 3.5% during the first quarter and gained an impressive 62,863 more shares valued at $323,092,000. JPMorgan Chase & Co. also seized the opportunity in the fourth quarter as they purchased an additional 58,365 shares worth $147,020,000. Lastly,Mackenzie Financial Corp took advantage of a similar situation when they increased their holdings by 3.8% in the fourth quarter through purchasing an extra 38 ,517 shares valued at $86 ,977 ,000.
Now it seems that hedge funds and other institutional investors own approximately 95.70% of Amedisys stock as of August 30th.
On another note,Amedisys opened at $93.79 on Tuesday with a fifty-day simple moving average of $91.63 and a two-hundred day simple moving average of $85 .40.That being said,the health services provider boasts a current ratio and quick ratio of 0.92 respectively.The company has a market capitalization that reaches towards $3 .06 billion with a price-to-earnings ratio amassing around 1 ,340 .05 The price-to-earnings-growth ratio stands at roughly2 .54 alongside a beta that hovers around1 .04
A number of research analysts have shared their thoughts and evaluations about Amedisys recently. Benchmark, for example, downgraded the company’s rating from “buy” to “hold”. TD Cowen, meanwhile, raised their target price from $84.00 to $101.00 and gave the stock a “market perform” rating.
StockNews.com began coverage of Amedisys with a “buy” rating. Barclays also increased their target price from $88.00 to $101.00 while Cantor Fitzgerald raised theirs from $91.00 to $100 in recent reports.Since then,a total of ten equities research analysts have given the stock a “hold” rating while four have provided a “buy” rating.The average target price according to Bloomberg.com is currently at$109 .60.
These developments merit close attention as they directly impact the market perception and performance of Amedisys, Inc.. With continuous modifications in holdings by hedge funds and institutional investors alongside varying ratings from research analysts, it becomes increasingly perplexing for investors to form an accurate assessment of the company’s projected growth and future prospects.
Source: beststocks.com
